connecting the dots to find a cure for Systemic Juvenile Idiopathic Arthritis

Donate DONATE
MENUMENU
  • Home
  • Research Focus
  • Events
    • - Family Conf: 2019
    • - Family Conf: 2018 (past)
    • - NextGen Therapies - 2017
    • - Family Day: 2017
    • - NextGen Therapies: 2016
  • Patient Resources
    • Find Clinical Trials
    • Parents Advisory Board
  • About Us
  • Blog
  • Join Us
Home > Clinical Trials > IL 18 Binding Protein (tadekinig alfa) gets Breakthrough Therapy and Orphan status from FDA

IL 18 Binding Protein (tadekinig alfa) gets Breakthrough Therapy and Orphan status from FDA

Jonathan Boutelle | April 4, 2017 | 4 Comments

The Swiss biotech company AB2Bio has been working for some time on tadekinig alfa, a medicine that blocks the IL18 pathway. Today they received news that the medicine has been granted both “Breakthrough Therapy” and “Orphan” status by the FDA.

What does this mean for SJIA? Well, IL18 seems to be an important pathway in MAS, which is the mostdangerous side-effect of SJIA. So blocking the IL18 pathway might be a useful treatment for patients with SJIA. But the drug has NOT been approved yet (although the Phase I and Phase II clinical trials so far have shown an excellent safety profile). “Breakthrough Therapy” status means that the FDA will work with the company to expedite the approval process. And “Orphan” Status means that they will get tax credits for clinical testing, and won’t have to pay certain fees to the FDA.

The drug is being tested for HLH and other life-threatening conditions of severe systemic autoinflammation.Clinical trials are also being done in Adult-Onset Stills Disease (which is essentially SJIA in adults).

We don’t know when tadekinig alfa will be available in the US, but this news definitely means it will be arriving on an accelerated timetable. We’ll let you know more as we find out more!

Comments

  1. Cindy Depew says

    January 12, 2018 at 7:26 am

    This is awesome news!!! My grandson is currently in a drug trial for this medication. It is saving his life!! Please expedite it!! We need it for Landen!!!

    Reply
  2. Danielle Shedd says

    January 12, 2018 at 9:41 am

    Landen is my nephew and this is life changing for him! This needs to be approved ASAP!

    Reply
  3. Jody says

    January 13, 2018 at 10:12 am

    Landen is a special, special boy and this drug is saving his life. Please expedite!!!!!! ASAP

    Reply
  4. Catherine says

    July 31, 2018 at 1:41 pm

    So, I recommended this(TADEKINK ALFA) I did my research to the family’s father, he did what he had to do, Laden will be fine!!! God Bless….Jesus knows!!! Its a trial that has worked, and he will survive, just remember to all that God is Great, this will all surpass…as having a person who can’t touch him heal him from afar. I told his father he would have a son, and he would be special. Please for the grace of God, treat this child as such!!! He is a living, breathing, son of God…if we come to God for our problems, he solves them quickly…I love this child and I don’t know him, but I do!! Does this make sense..thank you to everyone who believes in God, he is the Omega!!!

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sign Up For Email Updates

Browse by Topic

  • NextGen Drugs
  • Events
  • Clinical Trials
  • Photos & Videos
  • Community Posts

Recent Comments

  • 22 Jan 2019
    Frank Jones said:Sorry guys, I thought this was an email not a public comment. Thank… on - Systemic JIA Foundation is a IRS approved 501(c)(3) charity now
  • 22 Jan 2019
    Frank Jones said:Hello, I am a father of a SJIA kid. We are having a fund raiser at my work and… on - Systemic JIA Foundation is a IRS approved 501(c)(3) charity now
  • 26 Sep 2018
    Jeanne said:I have had problems with my ears for the past 30 years due to inflammation. I have been put… on - Vamorolone: A steroid replacement with fewer side effects
  • 31 Jul 2018
    Catherine said:So, I recommended this(TADEKINK ALFA) I did my research to the family's father, he did what he had to do,… on - IL 18 Binding Protein (tadekinig alfa) gets Breakthrough Therapy and Orphan status from FDA
  • 20 Jun 2018
    Maria Torresan said:I have a rare disease call Idiopathic Subglottic Stenosis. Where my body is attacking its self creating scar tissue that… on - Vamorolone: A steroid replacement with fewer side effects

More Comments

Blog Archives

  • December 2018
  • May 2018
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • January 2017
  • October 2016

More Archives

Populer Blog Posts

  • Save the date for 2019 SJIA Family Conference: June 28th & 29th
  • Systemic JIA Foundation is a IRS approved 501(c)(3) charity now
  • Systemic JIA Family Conference this week & Schedule for first day

More from The Blog

Tags

Actemra Advise for Patients Anakinra Canakinumab Clinical Trials Conferences Family Day IL18 Ilaris Kineret Lung Disease lung infection mas Methotrexate New Drugs Next-Gen Conference Patients Patients Stories Photos pjp Research sjia SJIA Community SJIA Drugs SJIA Foundation SJIA in Media SJIA Meds Steroids Tocilizumab Video Presentations

Contact Us!

Quick Links

  • About Us
  • Research Focus
  • Parents Advisory Board
  • Blog
  • Join Us

For Patients

  • Patient Resources
  • Find Clinical Trials

Donate

  • Donate to SJIA Research

Contact Us

Location 3584 Outlook Avenue, Cincinnati OH, 45208

Email Address info@systemicjia.org

SIGN UP FOR EMAIL UPDATES

© 2019 The Systemic JIA Foundation is a 501(c)(3) non-profit organization. All Rights Reserved.

Disclaimer

This website is provided for educational and informational purposes only. Systemic JIA Foundation is not engaged in rendering medical advice or professional services and this information should not be used for diagnosing or treating a health problem. The site authors and the content providers make no representation or warranties, expressed or implied. Providing links to other websites does not imply that Systemic JIA Foundation endorses the information or services provided on those websites. The organizations operating those websites are solely responsible for the content found on their websites.